Patents by Inventor Henry Brem

Henry Brem has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11191853
    Abstract: A marker for imaging includes a bio-dissolvable material and a contrast agent configured to provide contrast during an imaging procedure. A method can include forming a marker for imaging from a bio-dissolvable material and impregnating the bio-dissolvable material with a contrast agent. A method can include implanting a bio-dissolvable marker for imaging into a patient.
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: December 7, 2021
    Assignee: The Johns Hopkins University
    Inventors: Michael Lim, Henry Brem, Betty Tyler, Jason Liauw, Sheng-Fu Lo
  • Publication number: 20210077434
    Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.
    Type: Application
    Filed: November 13, 2020
    Publication date: March 18, 2021
    Inventors: DIMITRIOS MATHIOS, BETTY TYLER, DREW PARDOLL, HENRY BREM, MICHAEL LIM
  • Patent number: 10864180
    Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: December 15, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim
  • Publication number: 20200001121
    Abstract: An embodiment in accordance with the present invention provides a transducer design for minimally invasive focused ultrasound (MIFU). The present invention allows flexible control of a focused ultrasound wave using mechanical and electrical control. The transducer array is implemented on a flexible substrate that can be mechanically controlled through two or more physical configurations. As with conventional electronic “steering,” the transducer elements can be controlled electronically to provide adjustable focus of the ultrasound. The combination of mechanical and electronic control provides the device a very flexible method for delivering focused ultrasound. The invention also includes a design that allows integration of ultrasound and endoscopic image guidance. The ultrasound guidance includes anatomical visualization and functional imaging (e.g. blood flow and coagulation of vasculature). The ultrasound imaging transducer is used for thermometry within the region of interest for treatment.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 2, 2020
    Inventors: Amir Manbachi, Jeffrey Siewerdsen, Nicholas Ellens, Xiaoxuan Zheng, Micah Belzberg, Alan Cohen, Henry Brem
  • Patent number: 10195190
    Abstract: Local delivery formulations of the antineoplastic and microbicide agent acriflavine, and methods of making and using thereof are significantly more efficacious at increasing the median survival of subjects with proliferative disease than systemic administrations of acriflavine. The local delivery formulations of acriflavine show a dose-dependent increase in the median survival of subjects. The local delivery forms provide the increased efficacy without the toxicity associated with systemic administration of the agent.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: February 5, 2019
    Assignee: The Johns Hopkins University
    Inventors: Henry Brem, Antonella Mangraviti, Alessandro Olivi, Betty M. Tyler, Tula Raghavan
  • Publication number: 20180036301
    Abstract: Local delivery formulations of the antineoplastic and microbicide agent acriflavine, and methods of making and using thereof are significantly more efficacious at increasing the median survival of subjects with proliferative disease than systemic administrations of acriflavine. The local delivery formulations of acriflavine show a dose-dependent increase in the median survival of subjects. The local delivery forms provide the increased efficacy without the toxicity associated with systemic administration of the agent.
    Type: Application
    Filed: February 11, 2016
    Publication date: February 8, 2018
    Inventors: Henry Brem, Antonella Mangraviti, Alessandro Olivi, Betty M. Tyler, Tula Raghavan
  • Publication number: 20170274102
    Abstract: A marker for imaging includes a bio-dissolvable material and a contrast agent configured to provide contrast during an imaging procedure. A method can include forming a marker for imaging from a bio-dissolvable material and impregnating the bio-dissolvable material with a contrast agent. A method can include implanting a bio-dissolvable marker for imaging into a patient.
    Type: Application
    Filed: August 14, 2015
    Publication date: September 28, 2017
    Inventors: Michael Lim, Henry Brem, Betty Tyler, Jason Liauw, Sheng-Fu Lo
  • Publication number: 20160310453
    Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 27, 2016
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: DIMITRIOS MATHIOS, BETTY TYLER, DREW PARDOLL, HENRY BREM, MICHAEL LIM
  • Patent number: 8895597
    Abstract: The additive effect of combined intracranial carmustine (“BCNU”) with intracranial temozolomide (“TMZ”), and particularly in combination with radiation (“XRT”), in the treatment of two rat intracranial glioma models, the 9L gliosarcoma and the F98 glioma, demonstrates that local delivery of both drugs, especially in combination with radiation, is far more effective than delivery of either drug alone or one systemically and one locally, either with or without radiation. The triple therapy showed a significant improvement in survival when compared to controls (p=0.0004), local BCNU (p=0.0043), oral TMZ (p=0.0026), local TMZ (p=0.0105), and the combinations of either BCNU and XRT (p=0.0378) or oral TMZ and local BCNU (p=0.0154).
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: November 25, 2014
    Inventors: Violette Renard Recinos, Betty Tyler, Sarah Brem Sunshine, Henry Brem
  • Publication number: 20110313010
    Abstract: The additive effect of combined intracranial carmustine (“BCNU”) with intracranial temozolomide (“TMZ”), and particularly in combination with radiation (“XRT”), in the treatment of two rat intracranial glioma models, the 9L gliosarcoma and the F98 glioma, demonstrates that local delivery of both drugs, especially in combination with radiation, is far more effective than delivery of either drug alone or one systemically and one locally, either with or without radiation. The triple therapy showed a significant improvement in survival when compared to controls (p=0.0004), local BCNU (p=0.0043), oral TMZ (p=0.0026), local TMZ (p=0.0105), and the combinations of either BCNU and XRT (p=0.0378) or oral TMZ and local BCNU (p=0.0154).
    Type: Application
    Filed: June 17, 2011
    Publication date: December 22, 2011
    Inventors: Violette Renard Recinos, Betty Tyler, Sarah Brem Sunshine, Henry Brem
  • Publication number: 20080260834
    Abstract: Localized delivery of 1,25 D3 directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D3 have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D3 analogs for the treatment of intracranial tumors as well as neurodegenerative disorders such as Alzheimer's disease as well as to maximize the efficacy of these analogs in the treatment of systemic malignancies. The therapeutic efficacy of these formulations was demonstrated through a variety of studies in vitro and in vivo. Hybrid analogs of 1,25 D3 were incorporated into biodegradable polymer wafers composed of a polyanhydride copolymer of 1,3-bis(p-carboxyphenoxy)propane (CPP) and sebacic acid (SA) in a 20:80 molar ratio.
    Type: Application
    Filed: June 30, 2008
    Publication date: October 23, 2008
    Inventors: Martin Burke, Maria-Christina White, Mark C. Watts, Jae Kyoo Lee, Betty M. Tyler, Gary H. Posner, Henry Brem
  • Publication number: 20030105067
    Abstract: Localized delivery of 1,25 D3 directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D3 have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D3 analogs for the treatment of intracranial tumors as well as neurodegenerative disorders such as Alzheimer's disease as well as to maximize the efficacy of these analogs in the treatment of systemic malignancies. The therapeutic efficacy of these formulations was demonstrated through a variety of studies in vitro and in vivo. Hybrid analogs of 1,25 D3 were incorporated into biodegradable polymer wafers composed of a polyanhydride copolymer of 1,3-bis(p-carboxyphenoxy)propane (CPP) and sebacic acid (SA) in a 20:80 molar ratio.
    Type: Application
    Filed: August 20, 2002
    Publication date: June 5, 2003
    Applicant: The Johns Hopkins University
    Inventors: Martin Burke, Maria-Christina White, Mark C. Watts, Jae Kyoo Lee, Betty M. Tyler, Gary H. Posner, Henry Brem
  • Patent number: 6482810
    Abstract: Pharmaceutical compositions for delivering an effective dose of an angiogenesis inhibitor consisting of a tetracycline or tetracycline such as minocycline. The effective dosage for inhibition of angiogenesis based on in vitro testing is between one and 500 micromolar. The compositions are delivered topically, locally or systemically using implants or injection. The composition is extremely selective for growth of endothelial cells, inhibiting growth, but is not cytotoxic at the effective dosages.
    Type: Grant
    Filed: April 13, 1994
    Date of Patent: November 19, 2002
    Inventors: Henry Brem, Rafael J. Tamargo, Robert A. Bok
  • Publication number: 20020076442
    Abstract: Localized delivery of 1,25 D3 directly to a target area using biodegradable polymeric matrices maximizes the efficacy of this drug while minimizing systemic exposure and toxicity. Anticalcemic analogs of 1,25 D3 have also been incorporated into controlled release polymer formulations to achieve efficacious intracranial concentrations of 1,25 D3 analogs for the treatment of intracranial tumors as well as neurodegenerative disorders such as Alzheimer's disease as well as to maximize the efficacy of these analogs in the treatment of systemic malignancies. The therapeutic efficacy of these formulations was demonstrated through a variety of studies in vitro and in vivo. Hybrid analogs of 1,25 D3 were incorporated into biodegradable polymer wafers composed of a polyanhydride copolymer of 1,3-bis(p-carboxyphenoxy)propane (CPP) and sebacic acid (SA) in a 20:80 molar ratio. In addition to providing improved treatments for malignancies and neurodegenerative disorders.
    Type: Application
    Filed: September 2, 1998
    Publication date: June 20, 2002
    Inventors: MARTIN BURKE, MARIA-CHRISTINA WHITE, MARK C. WATTS, JAE KYOO LEE, BETTY M. TYLER, GARY H. POSNER, HENRY BREM
  • Patent number: 5846565
    Abstract: A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood-brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non-biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed.
    Type: Grant
    Filed: December 18, 1996
    Date of Patent: December 8, 1998
    Assignees: Massachusetts Institute of Technology, The Johns Hopkins University
    Inventors: Henry Brem, Robert S. Langer, Abraham J. Domb
  • Patent number: 5651986
    Abstract: A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood-brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended time period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non-biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed. The examples demonstrate the efficacy of paclitaxel and camptothecin delivered in polymeric implants prepared by compression molding of biodegradable and non-biodegradable polymers, respectively. The results are highly statistically significant.
    Type: Grant
    Filed: June 14, 1996
    Date of Patent: July 29, 1997
    Assignees: Massachusetts Institute of Technology, The Johns Hopkins University
    Inventors: Henry Brem, Robert S. Langer, Abraham J. Domb
  • Patent number: 5626862
    Abstract: A method and devices for localized delivery of a chemotherapeutic agent to solid tumors, wherein the agent does not cross the blood-brain barrier and is characterized by poor bioavailability and/or short half-lives in vivo, are described. The devices consist of reservoirs which release drug over an extended time period while at the same time preserving the bioactivity and bioavailability of the agent. In the most preferred embodiment, the device consists of biodegradable polymeric matrixes, although reservoirs can also be formulated from non-biodegradable polymers or reservoirs connected to implanted infusion pumps. The devices are implanted within or immediately adjacent the tumors to be treated or the site where they have been surgically removed. The examples demonstrate the efficacy of paclitaxel and camptothecin delivered in polymeric implants prepared by compression molding of biodegradable and non-biodegradable polymers, respectively. The results are highly statistically significant.
    Type: Grant
    Filed: August 2, 1994
    Date of Patent: May 6, 1997
    Assignees: Massachusetts Institute of Technology, The Johns Hopkins University
    Inventors: Henry Brem, Robert S. Langer, Abraham J. Domb
  • Patent number: 4075911
    Abstract: A drive mechanism for a reciprocating and multiple step index mechanism to achieve smooth starting and stopping action with controlled acceleration and decleration. It is characterized by extremely flexible kinematic characteristics achieved by the superposition of a constant velocity, fundamental and a higher harmonic component. The mechanism utilizes pairs of rotating drive members and eccentric members mounted in non-rotational relation, the pairs being connected to rotate in a multiple integral angular velocity ratio. An output member is arranged in driving relation to one of the eccentric members and is influenced also by the rotation of the other eccentric member. Power input is directed to one of the pairs of drive members.
    Type: Grant
    Filed: May 15, 1975
    Date of Patent: February 28, 1978
    Inventor: John Henry Brems
  • Patent number: 4018090
    Abstract: An intermittent reversible indexing system with a rotary input and rotary output which includes a natural dwell of the output at the end of each cycle with a smooth acceleration to a maximum velocity and subsequent deceleration to another dwell and a simple mechanism for changing the index stroke. A planetary carrier carrying a single planetary gear is driven about a first axis with the planetary gear in mesh with a stationary sun gear concentric about said first axis. A drive member in the form of a shaft eccentric to the axis of said planetary engages and slides in a slot of an output member, thereby driving said output member about a second axis displaced from said first axis. A movable mount for the output member changes the drive relationship with said eccentric shaft to change the index motion.
    Type: Grant
    Filed: May 15, 1975
    Date of Patent: April 19, 1977
    Inventor: John Henry Brems
  • Patent number: 3961607
    Abstract: An internal combustion engine construction to improve thermodynamic efficiency by providing, in addition to the standard cylinders and pistons, a supplemental cylinder connected to each combustion chamber of each cylinder and, a piston in each supplemental cylinder associated to move in conjunction with the standard pistons, the relationship of the association being such that the volume of the combustion chamber can be enlarged or ensmalled either by a manual control or an automatic control regulable in response to engine conditions and to modify the volume time relationship.
    Type: Grant
    Filed: May 12, 1972
    Date of Patent: June 8, 1976
    Inventor: John Henry Brems